GSK

GSK | NYSE

Price Alert Chart Builder DCF Calculator

$50.83

+$0.63 (+1.25%)

Sep 21, 2026, 9:41 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+1.25%

(1D)

Rating

Updated: Sep 7, 2026

60.1

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Full Analysis

Why Price Moved

6 days ago

+3.99%

Shares are trading higher after GSK presented data...

Key Statistics

Market Data

Market Cap $101.84B

1D Range

50.47 50.88

52W Range

39.29 61.70

Valuation (TTM)

PE 13

PB 4.33

EV/EBITDA 8.52

Valuation (NTM)

Forward PE 9.48

Forward PEG 2.26

Price Target $60

Cash Flow

FCF Yield 9.3%

SBC Adj. FCF Yield 9.3%

SBC Impact N/A

Margins

Gross Margin 73.3%

Operating Margin 26.5%

FCF Margin 21.0%

Growth (CAGR)

Revenue 3Y | 5Y 4.3% | 1.6%

Dil EPS 3Y | 5Y -27.5% | 5.5%

FCF 3Y | 5Y 38.0% | 5.8%

Returns

ROA 7.8%

ROE 28.4%

ROIC 16.0%

Financial Health

Net Debt

£15.04B ($19.94B)

Current Ratio 0.82

Interest Coverage 11.37

Dividends

Div Yield 3.62%

Payout Ratio 63.1%

FCF Payout Ratio 41.6%

All Key Statistics

Loading financial charts...

Profile

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical...

Sector Healthcare

Industry Drug Manufacturers - General

Employees 66,841

IPO Date Mar 27, 1980

Website www.gsk.com

Fiscal Year January - December

Full Company Profile

Latest News

5 days ago · marketbeat.com

GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline

GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company's senior vice president and global head of oncology research and development.

5 days ago · seekingalpha.com

GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

6 days ago · zacks.com

GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy

GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.

6 days ago · reuters.com

GSK strikes up to $750 million deal for cancer-targeting drug

GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug ‌designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences.

7 days ago · zacks.com

GSK Presents Jideytro Data for Potential Use in First-Line NSCLC

GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.

10 days ago · reuters.com

GSK to shut vaccine factory in Germany, putting 641 jobs at risk

GSK said on Friday it will be shutting down a vaccine factory in Dresden, Germany, which ‌its website showed produces flu and hepatitis shots, in the summer of 2027.

11 days ago · zacks.com

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff

GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.

12 days ago · seekingalpha.com

GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript

17 days ago · proactiveinvestors.co.uk

GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says

GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.